Key Highlights: Implications: Akums’ CDSCO/DCGI approval to manufacture colchicine 0.5 mg for cardiovascular risk reduction is a “first‑time‑in‑India” regulatory milestone that lets India’...
Key Highlights: Implications: Extensior catapults Abbott into the GLP-1 frenzy, grabbing prime shelf space before generics from Eris/Natco crash prices by half—think explosive Tier-2 growt...
